NCT04383002

High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients)

Use of High Dose Inhaled Nitric Oxide in Intubated Patients Admitted With COVID-19

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 21 (actual)
• Sponsor: University Health Network, Toronto · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Novel therapies are desperately needed for treatment of COVID-19 patients. At present, there are no proven interventions to prevent progression of the disease or to rapidly treat patients with COVID-19 related respiratory failure. Data on the original coronavirus -SARS pneumonia suggested that high dose (\>160ppm) inhaled Nitric Oxide could have beneficial effects also on COVID-19, due to the genomic similarities between these two coronaviruses (1-3). This study will test whether high dose inhaled nitric oxide is safe and can reverse virus burden and respiratory failure in patients on mechanical ventilation.

Conditions

• COVID-19

Interventions

Type	Name	Description
DRUG	Nitric Oxide	iNO will be given at 160ppm for 6 hours, once a day, for 2 days

Timeline

• Start date: 2020-09-02
• Primary completion: 2021-05-11
• Completion: 2021-06-11
• First posted: 2020-05-11
• Last updated: 2022-04-11

Locations

1 site across 1 country: Canada